EGFR and non-small cell lung carcinoma: Therefore, the use of osimertinib is recommended as first-line chemotherapy for EGFR-mutated NSCLC as well as other EGFR-TKIs with or without anti-Vascular Endothelial Growth Factor (VEGF) antibodies [9].